News
Public · Published
Alnylam Pharmaceuticals Price Target Cut to $199.00/Share From $376.00 by Bernstein
Bernstein cut its price target on Alnylam Pharmaceuticals to $199.00 per share from $376.00 and downgraded the stock to Market Perform from Outperform, according to ratings actions reported by Benzinga.
Published:
Updated:
What happened
Bernstein cut its price target on Alnylam Pharmaceuticals to $199.00 per share from $376.00 and downgraded the stock to Market Perform from Outperform, according to ratings actions reported by Benzinga.
Confirmed
Global impact / market context
A lower target and downgrade signal that this analyst expects less upside ahead for Alnylam, which can push some investors to reduce holdings or wait for clearer results before buying shares.
Analyst inference
Analyst rating changes often draw attention because they summarize one research firm's view of a company's prospects. The size of this target cut suggests Bernstein now sees materially less room for gains than before.
Analyst inference
What to watch
- Watch whether other research firms also lower their Alnylam price targets or ratings after Bernstein's move, since that would show whether the view is spreading. Confirmed
- Watch Alnylam's next earnings report for updates on revenue and costs, which could either support or challenge the case for a higher share price. Proposed
- Watch for signs that investors are selling Alnylam shares in response, such as unusually heavy trading, which would show the downgrade changed their buying and selling decisions. Analyst inference
Evidence
- Original source link unavailable